Evidence map›Paper›PMID 30891247›Full record

ArticleJournal of pharmaceutical policy and practice2019

Jazia prime vendor system- a public-private partnership to improve medicine availability in Tanzania: from pilot to scale.

Karin Wiedenmayer, Romuald Mbwasi, William Mfuko, Ezekiel Mpuya, James Charles, Fiona Chilunda, Denis Mbepera, Ntuli Kapologwe

Abstract read
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Acceptability of a Prime Vendor System in Public Healthcare Facilities in Tanzania.International journal of health policy and management · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Karin Wiedenmayer1Swiss Tropical and Public Health Institute, Basel, Switzerland.
Romuald Mbwasi3Senior pharmaceutical consultant, Dar es Salaam and senior lecturer at St. John's University of Tanzania, Dodoma, Tanzania.
William MfukoSenior pharmaceutical consultant, Dar es Salaam, Dodoma, Tanzania.
Ezekiel MpuyaHealth System Resource Center, President's Office Regional Administration and Local Government, Dodoma, Tanzania.
James CharlesRegional Medical Officer, Regional Administrative Secretary's Office, Dodoma, Tanzania.
Fiona ChilundaHealth Promotion and System Strengthening Project, Dodoma, Tanzania.
Denis MbeperaRegional Pharmacist, Regional Administrative Secretary's Office, Dodoma, Tanzania.
Ntuli KapologweDirector of Health Services, Social Welfare and Nutrition Services, President's Office of Regional Administration and Local Government, Dodoma, Tanzania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe availability of medicines in public health facilities in Tanzania is problematic. Medicines shortages are often caused by unavailability at Medical Stores Department, the national supplier for public health facilities. During such stock-outs, districts may purchase from private suppliers. However, this procedure is intransparent, bureaucratic and uneconomic.

objectivesTo complement the national supply chain in case of stock-outs with a simplified, transparent and efficient procurement procedure based on a public-private partnership approach with a prime vendor at the regional level. To develop a successful pilot of a Prime Vendor system with the potential for national scale-up.

methodsA public-private partnership was established engaging one private sector pharmaceutical supplier as the Prime Vendor to provide the complementary medicines needed by public health facilities in Tanzania. The Dodoma pilot region endorsed the concept involving the private sector, and procedures to procure complementary supplies from a single vendor in a pooled regional contract were developed. A supplier was tendered and contracted based on Good Procurement Practice. Pilot implementation was guided by Standard Operating Procedures, and closely monitored with performance indicators. A 12-step approach for national implementation was applied including cascade training from national to facility level. Each selected vendor signed a contract with the respective regional authority.

resultsIn the pilot region, tracer medicines availability increased from 69% in 2014 to 94% in 2018. Prime vendor supplies are of assured quality and average prices are comparable to prices of Medical Stores Department. Procurement procedures are simplified, shortened, standardized, transparent and well-governed. Procurement capacity was enhanced at all levels of the health system. Proven successful, the Prime Vendor system pilot was rolled-out nationally, on government request, to all 26 regions of mainland Tanzania, covering 185 councils and 5381 health facilities.

conclusionThe Prime Vendor system complements regular government supply through a regional contract approach. It is anchored in the structures of the regional health administration and in the decentralisation policy of the country. This partnership with the private sector facilitates procurement of additional supplies within a culture of transparency and accountability. Regional leadership, convincing pilot results and policy dialogue have led to national roll-out. Transferring this smaller-scale supply chain intervention to other regions requires country ownership and support for sustainable operations.

Indexed as

Medicines managementNational roll-outPharmaceutical procurementPilot to scalePrime vendorPublic-private partnershipSupply chainTanzania

Identifiers

PMID30891247
PMCPMC6388475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.